Vasileios Karamouzos

Dr. Vasileios Karamouzos

General University Hospital of Patras, Pátrai, Greece
orcid
ICU Consultant

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Journal of Clinical Medicine Research
Verified
Journal Article
Open access
DVDimitrios Velissaris
Dimitrios Velissaris
NPNikolaos Pantzaris
Nikolaos Pantzaris
IKIoanna Koniari
Ioanna Koniari
NKNikolaos Koutsogiannis
Nikolaos Koutsogiannis
VKVasileios Karamouzos
Vasileios Karamouzos
JEJohn Ellul
John Ellul
Chronic inflammation is a well-established background process in many age-related diseases. Many recent studies investigate the use of various inflammatory biomarkers such as C-reactive protein (CRP), interleukin-6, and interleukin-1 as predictors of physical and cognitive performance among elders. The phenotype of frailty has also been associated with underlying inflammatory mechanisms. The aim of this article was to review the literature referring to the correlation of CRP serum levels and frailty in older individuals. We tried to identify all relevant publications regarding the relation of CRP as an index of frailty in the elderly and its potential use. Although many studies in the recent medical literature positively associate serum CRP levels and frailty in older individuals, some do not, and some raise some interesting questions and set the basis for future studies. The association of CRP and frailty in elder patients should be considered when clinicians interpret inflammatory biomarkers in various clinical settings in such patients. Well-designed, prospective clinical trials are warranted to better assess the role and pathophysiology of frailty in the elderly and its mechanisms as also the exact role of CRP as an inflammatory marker and as a prognostic index in this syndrome.

1 January 2015 in Journal of Clinical Medicine Research
Verified
Journal Article
Open access
PDF file
DVDimitrios Velissaris
Dimitrios Velissaris
VKVasileios Karamouzos
Vasileios Karamouzos
CPCharalampos Pierrakos
Charalampos Pierrakos
DADiamanto Aretha
Diamanto Aretha
MKMenelaos Karanikolas
Menelaos Karanikolas
Hypomagnesemia in Critically Ill Sepsis Patients

13 May 2021 in Cureus
Verified
Journal Article
Open access
DVDimitrios Velissaris
Dimitrios Velissaris
NZNicholas Zareifopoulos
Nicholas Zareifopoulos
VKVasileios Karamouzos
Vasileios Karamouzos
EKEvangelos Karanikolas
Evangelos Karanikolas
CPCharalampos Pierrakos
Charalampos Pierrakos
MKMenelaos Karanikolas
Menelaos Karanikolas
Sepsis is a condition characterized by high morbidity and mortality which is commonly encountered in an emergency and critical care setting. Despite a substantial body of research, the ideal biomarker for the diagnosis and prognostic stratification of septic patients remains unknown. This review aimed to summarize the publications referring to the validity of the biomarker presepsin when used for the detection, monitoring and prognosis in patients suffering with sepsis. This work is a narrative review based on a PubMed/Medline search conducted in order to identify all relevant publications referring to the use of presepsin in sepsis. Search was not limited by year of publication so all articles archived in the database would be retrieved. No article from before 2010 was identified. A total of 57 publications of the last decade were included, all of which support the use of presepsin as a biomarker for the assessment of septic patients. It has been used alone or in combination with commonly used biomarkers in the evaluation of patients with sepsis in settings such as the emergency department and the intensive care unit. It is useful in the initial workup of patients with suspected sepsis in the emergency setting and may be a predictive factor of mortality and the most severe complication of sepsis. Presepsin seems to be a valuable tool for the laboratory workup of sepsis, especially when used in conjunction with other biomarkers and clinical rating scores with an established role in this population. Further research is needed to evaluate the clinical implications of utilizing presepsin measurements in the workup of sepsis.

19 January 2017 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
Matthaios Papadimitriou-OlivgerisMatthaios Papadimitriou-Olivgeris
Matthaios Papadimitriou-Olivgeris
FFF. Fligou
F. Fligou
CBC. Bartzavali
C. Bartzavali
AZA. Zotou
A. Zotou
ASA. Spyropoulou
A. Spyropoulou
MMMARKOS N MARANGOS
MARKOS N MARANGOS

1 March 2018 in Journal of Translational Internal Medicine
Verified
Journal Article
Open access
NPNikolaos Pantzaris
Nikolaos Pantzaris
CPChristina Platanaki
Christina Platanaki
CPCharalampos Pierrako
Charalampos Pierrako
VKVasileios Karamouzos
Vasileios Karamouzos
DVDimitrios Velissaris
Dimitrios Velissaris
Background and Objectives: Neutrophil to lymphocyte ratio (NLR) as calculated from the white cell differential blood count is considered a promising marker for the prognosis of patients with various diseases, including sepsis. This study was designed to assess the possible use of neutrophil-to-lymphocyte ratio in the prediction of survival outcomes in patients with community acquired pneumonia (CAP). A secondary objective was to compare the prognostic accuracy of NLR with the commonly used severity scores of sepsis SOFA, APACHE II and SAPS II. Methods: This was a retrospective study based on data extracted from 26 patients suffering from acute CAP. The study period was from February 01, 2017 until April 30, 2017. All patients with CAP were presented in the Emergency Department (ED) of the University Hospital of Patras, Greece and were treated after admission in the Internal Medicine Department. The neutrophil-to-lymphocyte ratio (NLR) was calculated from the white blood cell count (WBC) values measured from a peripheral venous blood specimen drawn on admission. It was then compared with C-reactive protein (CRP) serum levels and the sepsis calculated prognostic scores APACHE II, SAPS II and SOFA. The impact of the above parameters was evaluated in relation to the final outcome. Results: The mean period of hospitalization for the enrolled patients was 9.3 days (SD 5.8 days). Twenty-four patients (92.3%) got finally discharged from the hospital and two (7.7%) died during the hospitalization. Mean NLR and serum CRP values on admission were 10.2 ± 8.8 (min 1.4; max 34.7) and 11.4 ± 11 mg/dL (min 0.4; max 42.6) respectively. Based on the correlation analysis, serum CRP was more strongly positively correlated with NLR (r = 0.543, P = 0.004), than total WBC (r = 0.454, P = 0.02). None of the biomarkers of inflammation measured or computed in the study (CRP, WBC, NLR) showed any correlation with either the days of hospitalization or the sepsis prognostic scores. Conclusions: NLR shows a statistical significant correlation to the commonly used inflammatory markers CRP and total WBC in the small sample size of patients with CAP that we assessed. Although NLR is a simple, cheap and rapidly available measurement in the ED, future, larger prospective studies are warranted to confirm its possible value as a prognostic index in sepsis patients with CAP.

19 May 2022 in Microorganisms
Verified
Journal Article
Open access
PDF file
Stelios F. AssimakopoulosStelios F. Assimakopoulos
Stelios F. Assimakopoulos
GEGerasimos Eleftheriotis
Gerasimos Eleftheriotis
MLMARIA LAGADINOU
MARIA LAGADINOU
VKVasileios Karamouzos
Vasileios Karamouzos
PDPeriklis Dousdampanis
Periklis Dousdampanis
MMMarkos Marangos
Markos Marangos
A considerable proportion of patients with severe COVID-19 meet Sepsis-3 criteria and share common pathophysiological mechanisms of multiorgan injury with bacterial sepsis, in absence of secondary bacterial infections, a process characterized as “viral sepsis”. The intestinal barrier exerts a central role in the pathophysiological sequence of events that lead from SARS-CoV-2 infection to severe systemic complications. Accumulating evidence suggests that SARS-CoV-2 disrupts the integrity of the biological, mechanical and immunological gut barrier. Specifically, microbiota diversity and beneficial bacteria population are reduced, concurrently with overgrowth of pathogenic bacteria (dysbiosis). Enterocytes’ tight junctions (TJs) are disrupted, and the apoptotic death of intestinal epithelial cells is increased leading to increased gut permeability. In addition, mucosal CD4(+) and CD8(+) T cells, Th17 cells, neutrophils, dendritic cells and macrophages are activated, and T-regulatory cells are decreased, thus promoting an overactivated immune response, which further injures the intestinal epithelium. This dysfunctional gut barrier in SARS-CoV-2 infection permits the escape of luminal bacteria, fungi and endotoxin to normally sterile extraintestinal sites and the systemic circulation. Pre-existing gut barrier dysfunction and endotoxemia in patients with comorbidities including cardiovascular disease, obesity, diabetes and immunosuppression predisposes to aggravated endotoxemia. Bacterial and endotoxin translocation promote the systemic inflammation and immune activation, which characterize the SARS-CoV-2 induced “viral sepsis” syndrome associated with multisystemic complications of severe COVID-19.